| Stereochemistry | ACHIRAL |
| Molecular Formula | C29H32ClN5O2 |
| Molecular Weight | 518.05 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=NC2=C(NC3=CC(CN4CCCC4)=C(O)C(CN5CCCC5)=C3)C6=CC=C(Cl)C=C6N=C2C=C1
InChI
InChIKey=DJUFPMUQJKWIJB-UHFFFAOYSA-N
InChI=1S/C29H32ClN5O2/c1-37-26-9-8-24-28(33-26)27(23-7-6-21(30)16-25(23)32-24)31-22-14-19(17-34-10-2-3-11-34)29(36)20(15-22)18-35-12-4-5-13-35/h6-9,14-16,36H,2-5,10-13,17-18H2,1H3,(H,31,32)
| Molecular Formula | C29H32ClN5O2 |
| Molecular Weight | 518.05 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Pyronaridine was developed in China and has been registered in that country since the 1980s. Outside China, none of the existing formulations is registered because of the failure to meet international regulatory standards. Pyronaridine is generally active against chloroquine-resistant parasites. Pyronaridine has been investigated for the treatment of Malaria. Pyronaridine targets hematin. Combination of pyronaridine with artesunate was indicated for the blood-stage treatment of both strains of malaria: P. falciparum and P. vivax. WHO currently recommends artesunate-pyronaridine in areas where other artemisinin-based combination therapies are failing.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
